Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
A Trial of GFH018 and Toripalimab in Combination with Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05386888
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
- Conditions
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Lu Wang, MD, PhD
- Target Recruit Count
- 70
- Registration Number
- NCT05350943
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 480
- Registration Number
- NCT05342194
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 212
- Registration Number
- NCT05340491
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, China
🇨🇳Guizhou Cancer Hospital, Guiyang, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-12-18
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 452
- Registration Number
- NCT05302284
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT05291910
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, China
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Registration Number
- NCT05253105
Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2022-02-15
- Lead Sponsor
- Xiangya Hospital of Central South University
- Target Recruit Count
- 116
- Registration Number
- NCT05240404
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- XIANG YANQUN
- Target Recruit Count
- 45
- Registration Number
- NCT05229315
- Locations
- 🇨🇳
Yanqun Xiang, Guangzhou, Guangdong, China
GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 146
- Registration Number
- NCT05215665
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.